Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revelation Biosciences, Inc. - Common Stock (NQ:REVB)

1.648 +0.088 (+5.67%)
Streaming Delayed Price Updated: 11:28 AM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revelation Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Via ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Via ACCESS Newswire
Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug
Via Stocktwits
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Via ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Via ACCESS Newswire
Revelation Biosciences Inc (NASDAQ:REVB) Reports Wider-Than-Expected Q2 2025 Loss, Extends Cash Runway to Year-End
Revelation Biosciences (REVB) reports Q2 2025 earnings with a wider-than-expected loss of $(7.01) per share. Cash runway extends to December 2025, while Phase 1b Gemini trial data for CKD is expected... 
Via Chartmill
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
US Stocks Likely To Open Higher: S&P 500 Sees 'Average Gain Of 6.1%' In 2nd Half, Expert Says
U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices were trading slightly higher. 
Via Benzinga
Topics Stocks
Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’
The company is nearing completion of enrollment in its Phase 1b Gemini trial for CKD, with topline results expected shortly. 
Via Stocktwits
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
From Revelation Biosciences, Inc.
Via Business Wire
Which stocks have an unusual volume on Wednesday?
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
Wondering what's happening in today's after-hours session?
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Unusual volume stocks in Tuesday's session
Unusual volume stocks are being observed in Tuesday's session. 
Via Chartmill
Tuesday's session: gap up and gap down stocks
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
Tuesday's pre-market session: top gainers and losers
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
From Revelation Biosciences, Inc.
Via Business Wire
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
From Revelation Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.